For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

CMP-001-007

Trial Overview

Official Title

A Multicenter Phase 2, Open Label Study Of Intratumoral CMP-001 In Combination With Intravenous Pembrolizumab In Subjects With Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma

Study Purpose

To determine the safety and efficacy of the study drug, CMP-001, when given in combination with pembrolizumab.

Diagnosis

Patient has recurrent or metastatic squamous cell carcinoma of the head and neck.

Eligibility

Incurable Recurrent/Metastatic HNSCC.

 No prior systemic therapy in recurrent/metastatic setting.

Measurable disease.

One lesion amiable to repeated IT injection.

Ineligible if PD within 3 months of curative therapy.

No prior immunotherapy.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

CMP-001 + Pembrolizumab may be given as an injection into patient’s skin or tumor.

For more information, visit ClinicalTrials.gov

Key Participation Requirements
Gender
Male or Female
Age
19 years and older
Enrollment Status
Recruiting
Phase
Phase II
Methodist Health System Trial Code
CMP-001-007